PHARMACOL RES 润色咨询

PHARMACOLOGICAL RESEARCH

出版年份:1989 年文章数:3070 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:3.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2024-01-27 P拾荒者 来自浙江省

    偏重的研究方向:肿瘤
    经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况

    13

    展开13条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2024-01-03 1225de92m39暂无昵称 来自广东省

    请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗?

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-11-01 ms1000000150741111 来自上海

    10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-06-03 1473ac4am82暂无昵称 来自四川省

    偏重的研究方向:肿瘤
    经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命

    10

    展开10条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2024-02-28 不死鸟的飞翔 来自重庆

    偏重的研究方向:肿瘤
    经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收

    5

    展开5条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-11-07 ms7000001072468055 来自北京

    请问综述的checklist有模板吗?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-09-07 ms7000000804202809 来自四川省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:单体;中药;综述
    经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2022-07-24 石烽

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:主动脉夹层
    经验分享:5.3 Submitted to Journal
    5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)
    5.10 Under Review
    6.10 Required Reviews Completed
    6.12 Decision in Process
    6.14 Major Revise (20天期限)
    7.2 Resubmitted to Journal
    7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)
    7.11 Under Review
    7.20 Required Reviews Completed
    7.20 Decision in Process
    7.23 Accept
    7.23 Pre-proof online (DOI )
    要点:
    1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。
    2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。
    3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核
    祝各位的Paper早日Accept !!!

    37

    展开37条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-12 ms1000001706153386

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:一审15天,一周修回,2小时后accept,效率奇高

    18

    展开18条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向:肿瘤<br>经验分享:邀请了8个审稿人,一周了没人接受审稿,哎,啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules,若我文章不属于这两项内容,这两个框框还需要进行勾选吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2166009, encodeId=2e03216600943, content=10月20日提交,当天过了大约两小时就with editor了,然后一直到11月1号还是没动静。请问这是送审了没更新状态还是编辑把这篇文章遗忘处理了呢?有小伙伴有过类似的情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=104e5520464, createdName=ms1000000150741111, createdTime=Wed Nov 01 09:10:36 CST 2023, time=2023-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向:肿瘤<br>经验分享:综述,周五晚上9点提交的,周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向:肿瘤<br>经验分享:刚接收了1篇,审稿1个月,给了2个月修改的时间,周末修回,3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:单体;中药;综述<br>经验分享:投稿审完,Decision in Process已经两个月了还没返回意见,这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:主动脉夹层<br>经验分享:5.3 Submitted to Journal<br>5.4 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>5.10 Under Review<br>6.10 Required Reviews Completed<br>6.12 Decision in Process<br>6.14 Major Revise (20天期限)<br>7.2 Resubmitted to Journal<br>7.3 With Editor (此阶段包含inviting reviewers时间,只有inviting reviewers接受邀请才会进入Review阶段)<br>7.11 Under Review<br>7.20 Required Reviews Completed<br>7.20 Decision in Process<br>7.23 Accept<br>7.23 Pre-proof online (DOI )<br>要点:<br>1.Pharmacological Research期刊的审稿效率很高,投稿后Editor如果觉得文章质量不高会在当天拒稿,如果投稿当天或者第二天没有decision inprocess,那文章基本上进入Review invitations sent环节,但投稿状态仍然显示With Editor,只有等inviting reviewers同意审稿,投稿状态才会变成Under Review。<br>2.一审1个月左右,编辑和评审对国人友好,文章语言没经过润色,但返修时编辑和评审都没提文章语言的问题。<br>3.文章在返修提交时候,系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images,可以不是全膜,只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核<br>祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:一审15天,一周修回,2小时后accept,效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=386, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:一审20天,给了一个月修回,修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-02 泪湿青衣

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享:一审20天,给了一个月修回,修回后第二天立马接收了

    31

    展开31条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分